Study Title	**MITO26:** **Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (Cs)**
Primary Objective	To determine the activity in terms of objective response rate by RECIST version 1.1 (Complete and Partial Response [CR + PR]) with trabectedin in patients advanced uterine and ovarian carcinosarcoma
Secondary Objectives	• Progression-free survival [the diagnosis of progression will be assessed by radiological criteria; CA 125 increases alone (GCIG criteria of progression) will not be considered as progression of disease without a radiological confirmation of progression]. • Overall survival • Duration of response • Toxicity profile of trabectedin in this patient population.
Inclusion Criteria	• Histologically documented Stage I-IV or recurrent uterine or ovarian carcinosarcoma not amenable to surgery or radiotherapy • No more than 2 previous chemotherapy lines • PS 0-2 (ECOG) • Age> 18 • Measurable disease • Life expectancy of at least 3 months • Adequate organ functions: • Hematopoietic; Absolute neutrophil count ≥ 1,500/mm^3; Platelet count ≥ 100,000/mm^3; Hemoglobin ≥ 9 g/dL • Hepatic; AST and ALT ≤ 1.5 times upper limit of normal (ULN)* ; Alkaline phosphatase ≤ 2.5 times ULN* ; Bilirubin ≤ 1.5 times ULN NOTE: * ≤ 3 times ULN if liver metastases are present • Renal; Creatinine Clearance ≥ 45 mL/min or Serum Creatinine ≤1.5 x ULN • Serum Albumin >3.0 g/dL • Previous Brachytherapy treatment for uterine carcinosarcoma is allowed • No other invasive malignancy within the past 3 years except non-melanoma skin cancer • Written Informed Consent
Exclusion Criteria	• More than 2 previous chemotherapy lines • Single tumor lesion inside a previous irradiated filed • Pregnant (potentially fertile patients must be not in pregnancy during and for at least 3 months after study participation and must have a negative serum pregnancy test) • Active infection requiring antibiotics • Symptomatic peripheral neuropathy > grade 2 according to the NCI Common Toxicity Criteria. • Congestive heart failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year

	from study entry, uncontrolled high risk hypertension or arrhythmia. • Unstable or severe intercurrent medical condition that, in the opinion of the investigator, might interfere with achievement of study objectives • Psychological or sociological conditions, addictive disorders, or family problems, which would preclude compliance with the protocol
Number of Patients to enroll	16/43 enrolled patients (al 31.05.2018)

For Information	**Domenica Lorusso**	**domenica.lorusso@istitutotumori.mi.it**
	Iolanda Pulice	**iolanda.pulice@istitutotumori.mi.it**